

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

DATE OF BOARD MEETING

The board of directors (the “**Board**”) of Lanssen Pharmaceutical Holdings Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on 24 March 2023 (Friday) for the purpose of, amongst other matters, approving the publication of the annual results of the Company and its subsidiaries for the year ended 31 December 2022 and considering the declaration of a dividend, if any.

By order of the Board
Lanssen Pharmaceutical Holdings Limited
Pang Kai Fai
Company Secretary

Hong Kong, 14 March 2023

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen, Ms. Chan Ching Har, Eliza and Dr. Zhu Xun.